QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.108.146878v1 329/2/608    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Hawkins, P. M. Articles by Banks, W. A. Search for Related Content PubMed PubMed Citation Articles by Hawkins, P. M. Articles by Banks, W. A.

METABOLISM, TRANSPORT, AND PHARMACOGENOMICS

Permeability of the Blood-Brain Barrier to a Rhenacarborane

Saint Louis University School of Medicine, St. Louis, Missouri (P.M.H.); Department of Chemistry (P.A.J., X.S.) and Division of Geriatrics, Department of Internal Medicine (W.A.B.), Saint Louis University School of Medicine, St. Louis, Missouri; Department of Oral Anatomy, Showa University School of Dentistry, Tokyo, Japan (N.N.); Department of First Anatomy, Showa University School of Medicine, Tokyo, Japan (N.N.); and Geriatric Research, Education and Clinical Center, Veterans Affairs Medical Center, St. Louis, Missouri (W.A.B.)

The treatment of brain malignancies with boron neutron capture therapy depends on their ability to cross the blood-brain barrier (BBB). An especially promising class of boron-containing compounds is the rhenacarboranes that, if able to cross the BBB, could act as delivery vehicles as well as a source of boron. Here, we examined the ability of the 3-NO-3,3-²-(2,2'-N₂C₁₀H₆(Me){(CH₂)₇¹³¹I}-4,4')-closo-3,1,2-ReC₂B₉H₁₁ (rhenacarborane) labeled with iodine-131 to be taken up into the bloodstream after subcutaneous administration and to cross the BBB. The ¹³¹I-rhenacarborane was quickly absorbed from the injection site and reached a steady state in arterial serum of 2.59%/ml of the administered dose. Between 73 and 95% of the radioactivity in serum 6 h after administration represented intact ¹³¹I-rhenacarborane. Its octanol/buffer partition coefficient was 1.74, showing it to be lipophilic. Tissue/serum ratios for brain, lung, and liver showed classic patterns for a lipid-soluble substance with high levels immediately achieved and rapid redistribution. For brain, a steady state of approximately 0.107% of the administered dose/gram-brain was rapidly reached, and 71% of the radioactivity in brain 6 h after subcutaneous administration represented intact ¹³¹I-rhenacarborane. Steady-state values were 1.53 and 0.89% of the injected dose per gram for lung and liver, respectively. ¹³¹I-Rhenacarborane was quickly effluxed from brain by a nonsaturable system after its injection into the lateral ventricle of the brain. In conclusion, these results show that a rhenacarborane was enzymatically resistant and able to cross the BBB by transmembrane diffusion and accumulate in brain in substantial amounts. This supports their use as therapeutic agents for targeting the central nervous system.

Address correspondence to: Dr. William Allen Banks, 915 N. Grand Blvd., St. Louis, MO 63106. E-mail: bankswa{at}slu.edu